13 articles
Articles prepublished February 07, 2012
 |
|
Sample Size Reassessment in Non-inferiority Trials
Internal Pilot Study Designs with ANCOVA
Original Article
T. Friede (1), M. Kieser (2)
(1) Department of Medical Statistics, University of Göttingen, Göttingen, Germany; (2) Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
Summary
Objectives: Analysis of covariance (ANCOVA) is widely applied in practice and its use is recommended by regulatory guidelines. However, the required sample size for ANCOVA depends on parameters that are usually uncertain in the planning phase of a study. Sample size recalculation within the internal pilot study design allows to cope with this problem. From a regulatory viewpoint it is preferable that the treatment group allocation remains masked and that the type I error is controlled at the specified significance level. The characteristics of blinded sample size reassessment for ANCOVA in non-inferiority studies have not been investigated yet. We propose an appropriate method and evaluate its performance. Methods: In a simulation study, the characteristics of the proposed method with respect to type I error rate, power and sample size are investigated. It is illustrated by a clinical trial example how strict control of the significance level can be achieved. Results: A slight excess of the type I error rate beyond the nominal significance level was observed. The extent of exceedance increases with increasing non-inferiority margin and increasing correlation between outcome and covariate. The procedure assures the desired power over a wide range of scenarios even if nuisance parameters affecting the sample size are initially mis-specified. Conclusions: The proposed blinded sample size recalculation procedure protects from insufficient sample sizes due to incorrect assumptions about nuisance parameters in the planning phase. The original procedure may lead to an elevated type I error rate, but methods are available to control the nominal significance level.
Keywords
Clinical trials, Analysis of covariance, baseline adjustment, non-inferiority test, sample size recalculation
DOI
http://dx.doi.org/10.3414/ME09-01-0063You may also be interested in...
| 1. | ||
D. A. B. Lindberg, B. L. Humphreys IMIA Yearbook 2008 2008 3 1: 165-172 | ||
| 2. | ||
C. Normann Die Psychiatrie 2008 5 2: 127-133 | ||
| 3. | ||
Andreas E. May, Tobias Geisler, Meinrad Gawaz Thrombosis and Haemostasis 2008 99 3: 487-493 http://dx.doi.org/10.1160/TH07-11-0680 | ||
Preprint Online November 21, 2011
|
|
Sample Size Reassessment in Non-inferiority Trials
Internal Pilot Study Designs with ANCOVA
Original Article
T. Friede (1), M. Kieser (2)
(1) Department of Medical Statistics, University of Göttingen, Göttingen, Germany; (2) Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
Summary
Objectives: Analysis of covariance (ANCOVA) is widely applied in practice and its use is recommended by regulatory guidelines. However, the required sample size for ANCOVA depends on parameters that are usually uncertain in the planning phase of a study. Sample size recalculation within the internal pilot study design allows to cope with this problem. From a regulatory viewpoint it is preferable that the treatment group allocation remains masked and that the type I error is controlled at the specified significance level. The characteristics of blinded sample size reassessment for ANCOVA in non-inferiority studies have not been investigated yet. We propose an appropriate method and evaluate its performance. Methods: In a simulation study, the characteristics of the proposed method with respect to type I error rate, power and sample size are investigated. It is illustrated by a clinical trial example how strict control of the significance level can be achieved. Results: A slight excess of the type I error rate beyond the nominal significance level was observed. The extent of exceedance increases with increasing non-inferiority margin and increasing correlation between outcome and covariate. The procedure assures the desired power over a wide range of scenarios even if nuisance parameters affecting the sample size are initially mis-specified. Conclusions: The proposed blinded sample size recalculation procedure protects from insufficient sample sizes due to incorrect assumptions about nuisance parameters in the planning phase. The original procedure may lead to an elevated type I error rate, but methods are available to control the nominal significance level.
Keywords
Clinical trials, Analysis of covariance, baseline adjustment, non-inferiority test, sample size recalculation
DOI
http://dx.doi.org/10.3414/ME09-01-0063You may also be interested in...
| 1. | ||
D. A. B. Lindberg, B. L. Humphreys IMIA Yearbook 2008 2008 3 1: 165-172 | ||
| 2. | ||
C. Normann Die Psychiatrie 2008 5 2: 127-133 | ||
| 3. | ||
Andreas E. May, Tobias Geisler, Meinrad Gawaz Thrombosis and Haemostasis 2008 99 3: 487-493 http://dx.doi.org/10.1160/TH07-11-0680 | ||
Articles prepublished September 14, 2010
|
|
Sample Size Reassessment in Non-inferiority Trials
Internal Pilot Study Designs with ANCOVA
Original Article
T. Friede (1), M. Kieser (2)
(1) Department of Medical Statistics, University of Göttingen, Göttingen, Germany; (2) Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
Summary
Objectives: Analysis of covariance (ANCOVA) is widely applied in practice and its use is recommended by regulatory guidelines. However, the required sample size for ANCOVA depends on parameters that are usually uncertain in the planning phase of a study. Sample size recalculation within the internal pilot study design allows to cope with this problem. From a regulatory viewpoint it is preferable that the treatment group allocation remains masked and that the type I error is controlled at the specified significance level. The characteristics of blinded sample size reassessment for ANCOVA in non-inferiority studies have not been investigated yet. We propose an appropriate method and evaluate its performance. Methods: In a simulation study, the characteristics of the proposed method with respect to type I error rate, power and sample size are investigated. It is illustrated by a clinical trial example how strict control of the significance level can be achieved. Results: A slight excess of the type I error rate beyond the nominal significance level was observed. The extent of exceedance increases with increasing non-inferiority margin and increasing correlation between outcome and covariate. The procedure assures the desired power over a wide range of scenarios even if nuisance parameters affecting the sample size are initially mis-specified. Conclusions: The proposed blinded sample size recalculation procedure protects from insufficient sample sizes due to incorrect assumptions about nuisance parameters in the planning phase. The original procedure may lead to an elevated type I error rate, but methods are available to control the nominal significance level.
Keywords
Clinical trials, Analysis of covariance, baseline adjustment, non-inferiority test, sample size recalculation
DOI
http://dx.doi.org/10.3414/ME09-01-0063You may also be interested in...
| 1. | ||
D. A. B. Lindberg, B. L. Humphreys IMIA Yearbook 2008 2008 3 1: 165-172 | ||
| 2. | ||
C. Normann Die Psychiatrie 2008 5 2: 127-133 | ||
| 3. | ||
Andreas E. May, Tobias Geisler, Meinrad Gawaz Thrombosis and Haemostasis 2008 99 3: 487-493 http://dx.doi.org/10.1160/TH07-11-0680 | ||
Preprint Online August 05, 2011
|
|
Sample Size Reassessment in Non-inferiority Trials
Internal Pilot Study Designs with ANCOVA
Original Article
T. Friede (1), M. Kieser (2)
(1) Department of Medical Statistics, University of Göttingen, Göttingen, Germany; (2) Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
Summary
Objectives: Analysis of covariance (ANCOVA) is widely applied in practice and its use is recommended by regulatory guidelines. However, the required sample size for ANCOVA depends on parameters that are usually uncertain in the planning phase of a study. Sample size recalculation within the internal pilot study design allows to cope with this problem. From a regulatory viewpoint it is preferable that the treatment group allocation remains masked and that the type I error is controlled at the specified significance level. The characteristics of blinded sample size reassessment for ANCOVA in non-inferiority studies have not been investigated yet. We propose an appropriate method and evaluate its performance. Methods: In a simulation study, the characteristics of the proposed method with respect to type I error rate, power and sample size are investigated. It is illustrated by a clinical trial example how strict control of the significance level can be achieved. Results: A slight excess of the type I error rate beyond the nominal significance level was observed. The extent of exceedance increases with increasing non-inferiority margin and increasing correlation between outcome and covariate. The procedure assures the desired power over a wide range of scenarios even if nuisance parameters affecting the sample size are initially mis-specified. Conclusions: The proposed blinded sample size recalculation procedure protects from insufficient sample sizes due to incorrect assumptions about nuisance parameters in the planning phase. The original procedure may lead to an elevated type I error rate, but methods are available to control the nominal significance level.
Keywords
Clinical trials, Analysis of covariance, baseline adjustment, non-inferiority test, sample size recalculation
DOI
http://dx.doi.org/10.3414/ME09-01-0063You may also be interested in...
| 1. | ||
D. A. B. Lindberg, B. L. Humphreys IMIA Yearbook 2008 2008 3 1: 165-172 | ||
| 2. | ||
C. Normann Die Psychiatrie 2008 5 2: 127-133 | ||
| 3. | ||
Andreas E. May, Tobias Geisler, Meinrad Gawaz Thrombosis and Haemostasis 2008 99 3: 487-493 http://dx.doi.org/10.1160/TH07-11-0680 | ||
Preprint Online July 26, 2011
|
|
Sample Size Reassessment in Non-inferiority Trials
Internal Pilot Study Designs with ANCOVA
Original Article
T. Friede (1), M. Kieser (2)
(1) Department of Medical Statistics, University of Göttingen, Göttingen, Germany; (2) Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
Summary
Objectives: Analysis of covariance (ANCOVA) is widely applied in practice and its use is recommended by regulatory guidelines. However, the required sample size for ANCOVA depends on parameters that are usually uncertain in the planning phase of a study. Sample size recalculation within the internal pilot study design allows to cope with this problem. From a regulatory viewpoint it is preferable that the treatment group allocation remains masked and that the type I error is controlled at the specified significance level. The characteristics of blinded sample size reassessment for ANCOVA in non-inferiority studies have not been investigated yet. We propose an appropriate method and evaluate its performance. Methods: In a simulation study, the characteristics of the proposed method with respect to type I error rate, power and sample size are investigated. It is illustrated by a clinical trial example how strict control of the significance level can be achieved. Results: A slight excess of the type I error rate beyond the nominal significance level was observed. The extent of exceedance increases with increasing non-inferiority margin and increasing correlation between outcome and covariate. The procedure assures the desired power over a wide range of scenarios even if nuisance parameters affecting the sample size are initially mis-specified. Conclusions: The proposed blinded sample size recalculation procedure protects from insufficient sample sizes due to incorrect assumptions about nuisance parameters in the planning phase. The original procedure may lead to an elevated type I error rate, but methods are available to control the nominal significance level.
Keywords
Clinical trials, Analysis of covariance, baseline adjustment, non-inferiority test, sample size recalculation
DOI
http://dx.doi.org/10.3414/ME09-01-0063You may also be interested in...
| 1. | ||
D. A. B. Lindberg, B. L. Humphreys IMIA Yearbook 2008 2008 3 1: 165-172 | ||
| 2. | ||
C. Normann Die Psychiatrie 2008 5 2: 127-133 | ||
| 3. | ||
Andreas E. May, Tobias Geisler, Meinrad Gawaz Thrombosis and Haemostasis 2008 99 3: 487-493 http://dx.doi.org/10.1160/TH07-11-0680 | ||
Preprint Online March 21, 2011
|
|
Sample Size Reassessment in Non-inferiority Trials
Internal Pilot Study Designs with ANCOVA
Original Article
T. Friede (1), M. Kieser (2)
(1) Department of Medical Statistics, University of Göttingen, Göttingen, Germany; (2) Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
Summary
Objectives: Analysis of covariance (ANCOVA) is widely applied in practice and its use is recommended by regulatory guidelines. However, the required sample size for ANCOVA depends on parameters that are usually uncertain in the planning phase of a study. Sample size recalculation within the internal pilot study design allows to cope with this problem. From a regulatory viewpoint it is preferable that the treatment group allocation remains masked and that the type I error is controlled at the specified significance level. The characteristics of blinded sample size reassessment for ANCOVA in non-inferiority studies have not been investigated yet. We propose an appropriate method and evaluate its performance. Methods: In a simulation study, the characteristics of the proposed method with respect to type I error rate, power and sample size are investigated. It is illustrated by a clinical trial example how strict control of the significance level can be achieved. Results: A slight excess of the type I error rate beyond the nominal significance level was observed. The extent of exceedance increases with increasing non-inferiority margin and increasing correlation between outcome and covariate. The procedure assures the desired power over a wide range of scenarios even if nuisance parameters affecting the sample size are initially mis-specified. Conclusions: The proposed blinded sample size recalculation procedure protects from insufficient sample sizes due to incorrect assumptions about nuisance parameters in the planning phase. The original procedure may lead to an elevated type I error rate, but methods are available to control the nominal significance level.
Keywords
Clinical trials, Analysis of covariance, baseline adjustment, non-inferiority test, sample size recalculation
DOI
http://dx.doi.org/10.3414/ME09-01-0063You may also be interested in...
| 1. | ||
D. A. B. Lindberg, B. L. Humphreys IMIA Yearbook 2008 2008 3 1: 165-172 | ||
| 2. | ||
C. Normann Die Psychiatrie 2008 5 2: 127-133 | ||
| 3. | ||
Andreas E. May, Tobias Geisler, Meinrad Gawaz Thrombosis and Haemostasis 2008 99 3: 487-493 http://dx.doi.org/10.1160/TH07-11-0680 | ||
Preprint Online March 04, 2011
|
|
Sample Size Reassessment in Non-inferiority Trials
Internal Pilot Study Designs with ANCOVA
Original Article
T. Friede (1), M. Kieser (2)
(1) Department of Medical Statistics, University of Göttingen, Göttingen, Germany; (2) Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
Summary
Objectives: Analysis of covariance (ANCOVA) is widely applied in practice and its use is recommended by regulatory guidelines. However, the required sample size for ANCOVA depends on parameters that are usually uncertain in the planning phase of a study. Sample size recalculation within the internal pilot study design allows to cope with this problem. From a regulatory viewpoint it is preferable that the treatment group allocation remains masked and that the type I error is controlled at the specified significance level. The characteristics of blinded sample size reassessment for ANCOVA in non-inferiority studies have not been investigated yet. We propose an appropriate method and evaluate its performance. Methods: In a simulation study, the characteristics of the proposed method with respect to type I error rate, power and sample size are investigated. It is illustrated by a clinical trial example how strict control of the significance level can be achieved. Results: A slight excess of the type I error rate beyond the nominal significance level was observed. The extent of exceedance increases with increasing non-inferiority margin and increasing correlation between outcome and covariate. The procedure assures the desired power over a wide range of scenarios even if nuisance parameters affecting the sample size are initially mis-specified. Conclusions: The proposed blinded sample size recalculation procedure protects from insufficient sample sizes due to incorrect assumptions about nuisance parameters in the planning phase. The original procedure may lead to an elevated type I error rate, but methods are available to control the nominal significance level.
Keywords
Clinical trials, Analysis of covariance, baseline adjustment, non-inferiority test, sample size recalculation
DOI
http://dx.doi.org/10.3414/ME09-01-0063You may also be interested in...
| 1. | ||
D. A. B. Lindberg, B. L. Humphreys IMIA Yearbook 2008 2008 3 1: 165-172 | ||
| 2. | ||
C. Normann Die Psychiatrie 2008 5 2: 127-133 | ||
| 3. | ||
Andreas E. May, Tobias Geisler, Meinrad Gawaz Thrombosis and Haemostasis 2008 99 3: 487-493 http://dx.doi.org/10.1160/TH07-11-0680 | ||
Articles
You've 177 Article(s) in your Basket.
Methods News
5 Fachzeitschriften feiern 2012 "runde" Jubiläen
2012 feiern gleich fünf der 21 Fachzeitschriften "runde" Jubiläen, die im Schattauer...
Methods issue 1/2012
Monitoring and analyzing physiological parameters under different conditions of health and disease...
Methods issue 6/2011
This issue of Methods of Information in Medicine celebrates the journal‘s first 50 years. As the...
Call for Papers
We are inviting submissions for a Focus Theme in Methods of Information in Medicine on "Web...
Invitation to Apply for the Student Editorial Board 2012/2013
The Journal Methods of Information in Medicine is now accepting applications from trainees who...
Methods issue 5/2011
In 2008 it was decided that Methods of Information in Medicine will continue the tradition of...